Pancreatic Cancer Research

ResearcherKyushu UniversityNo recent work listed

Norihiro Sato

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2739-9790; OpenAlex author ID A5101932665. Sources: OpenAlex.

Their work

Papers
19 (first author 13, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 6 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers

Papers 19

  1. Concurrent Overexpression of Two Hyaluronidases, KIAA1199 and TMEM2, Strongly Predicts Shorter Survival After Resection in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/mpa.0000000000002106↗
  2. Prognostic and functional role of hyaluronan-binding protein 1 in pancreatic ductal adenocarcinoma. First author DOI 10.3892/ol.2022.13343↗
  3. Hypoxia increases KIAA1199/CEMIP expression and enhances cell migration in pancreatic cancer. First author DOI 10.1038/s41598-021-97752-z↗
  4. Hypoxia Increases KIAA1199/CEMIP Expression and Enhances Cell Migration in Pancreatic Cancer First author DOI 10.21203/rs.3.rs-219524/v1↗
  5. Overexpression of transmembrane protein 2 (TMEM2), a novel hyaluronidase, predicts poor prognosis in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2020.08.026↗
  6. Negative regulation between the expression levels of receptor for hyaluronic acid-mediated motility and hyaluronan leads to cell migration in pancreatic cancer. Last author DOI 10.3892/ol.2020.12060↗
  7. Hyaluronan activated-metabolism phenotype (HAMP) in pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.27172↗
  8. 4-Methylumbelliferone inhibits enhanced hyaluronan synthesis and cell migration in pancreatic cancer cells in response to tumor-stromal interactions. First author DOI 10.3892/ol.2018.8147↗
  9. KIAA1199/CEMIP/HYBID overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2016.12.007↗
  10. KIAA1199 is induced by inflammation and enhances malignant phenotype in pancreatic cancer. First author DOI 10.18632/oncotarget.15052↗
  11. A novel epigenetic mechanism regulating hyaluronan production in pancreatic cancer cells. First author DOI 10.1007/s10585-015-9771-9↗
  12. Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.apsb.2016.01.002↗
  13. Increased Expression of HYAL1 in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/mpa.0000000000000670↗
  14. Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight. Co-author DOI 10.1111/cas.12913↗
  15. Hyaluromycin, a Novel Hyaluronidase Inhibitor, Attenuates Pancreatic Cancer Cell Migration and Proliferation. First author DOI 10.1155/2016/9063087↗
  16. Hyaluronan stimulates pancreatic cancer cell motility. Last author DOI 10.18632/oncotarget.6617↗
  17. Receptor for Hyaluronic Acid-Mediated Motility is Associated with Poor Survival in Pancreatic Ductal Adenocarcinoma. First author DOI 10.7150/jca.12990↗
  18. Prognostic impact of hyaluronan and its regulators in pancreatic ductal adenocarcinoma. First author DOI 10.1371/journal.pone.0080765↗
  19. MicroRNA-10a is overexpressed in human pancreatic cancer and involved in its invasiveness partially via suppression of the HOXA1 gene. Co-author DOI 10.1245/s10434-012-2252-3↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shiro Kohi · 17 shared papers, 2013–2022 · strength 1.68
  2. Keiji Hirata · 16 shared papers, 2015–2022 · strength 1.62
  3. Atsuhiro Koga · 13 shared papers, 2015–2022 · strength 1.25
  4. Yuzan Kudo · 6 shared papers, 2019–2022 · strength 0.83
  5. Yasuhiro Adachi · 5 shared papers, 2020–2022 · strength 0.71
  6. Xiaobo Cheng · 9 shared papers, 2013–2020 · strength 0.70
  7. Takuya Oba · 4 shared papers, 2021–2022 · strength 0.60
  8. Toshiyuki Nakayama · 3 shared papers, 2020–2022 · strength 0.43
  9. Michael Goggins · 2 shared papers, 2016–2019 · strength 0.21
  10. Hanxing Tong · 1 shared paper, 2020 · strength 0.11
  11. Lili Wu · 1 shared paper, 2020 · strength 0.11
  12. Yuhong Zhou · 1 shared paper, 2020 · strength 0.11
  13. Masanori Hisaoka · 1 shared paper, 2017 · strength 0.08
  14. Yasuhiro Igarashi · 1 shared paper, 2016 · strength 0.07
  15. Koji Yamaguchi · 1 shared paper, 2013 · strength 0.05
  16. Makoto Hashizume · 1 shared paper, 2012 · strength 0.03
  17. Lin Cui · 1 shared paper, 2012 · strength 0.03
  18. Masafumi Nakamura · 1 shared paper, 2012 · strength 0.03
  19. Kenoki Ohuchida · 1 shared paper, 2012 · strength 0.03
  20. Takao Ohtsuka · 1 shared paper, 2012 · strength 0.03
  21. Masao Tanaka · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.